Brought to you by 
Evotec AG and Padlock ally to develop autoimmune disorder candidates
28 Mar 2016
Executive Summary
Evotec AG and Padlock Therapeutics Inc. have partnered to develop protein-arginine deiminase (PAD) inhibitor candidates for autoimmune diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Evotec AG and Padlock ally to develop autoimmune disorder candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice